Cytek Biosciences legal officer to depart

Did Cytek Biosciences (CTKB) report any disagreement related to Valerie Barnett’s departure?

Rhea-AI Filing Summary

FAQ

Filing Exhibits & Attachments

8-K Event Classification

Key Figures

Key Terms

What executive change did Cytek Biosciences (CTKB) disclose?

When will Valerie Barnett’s role at Cytek Biosciences (CTKB) end?

What positions did Valerie Barnett hold at Cytek Biosciences (CTKB)?

Which Cytek Biosciences (CTKB) executive signed the June 2026 report?

Cytek Biosciences stated that Valerie Barnett’s separation is not due to any disagreement with the company’s operations, policies, or practices. This language signals an orderly change rather than a dispute-driven departure in the legal leadership.

Cytek Biosciences, Inc. reports that Valerie Barnett will leave her role as Chief Legal Officer and Corporate Secretary.

Accepted by SEC EDGAR 06/25/2026 - 04:32 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Cytek Biosciences, Inc. reports that Valerie Barnett will leave her role as Chief Legal Officer and Corporate Secretary. The company and Ms. Barnett agreed that her position will terminate effective June 29, 2026.

The company states that Ms. Barnett’s separation is not due to any disagreement with its operations, policies, or practices, indicating an orderly leadership transition in its legal and corporate governance functions.

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Agreement date: June 18, 2026 Effective termination date: June 29, 2026 Commission File Number: 001-40632

3 metrics

Agreement date June 18, 2026 Date company and Valerie Barnett agreed to terminate position

Effective termination date June 29, 2026 End of Chief Legal Officer and Corporate Secretary role

Commission File Number 001-40632 Cytek Biosciences SEC registration reference

Chief Legal Officer, Corporate Secretary, Emerging growth company, Securities Exchange Act of 1934

4 terms

Chief Legal Officer financial

"Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate"

A chief legal officer is a senior executive responsible for overseeing a company's legal matters, ensuring that its activities comply with laws and regulations. They act like a company's legal guide, helping to prevent legal problems and manage risks. For investors, understanding this role is important because it reflects how well a company manages legal risks that could impact its stability and reputation.

Corporate Secretary financial

"Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate"

A corporate secretary is a person in a company who helps organize meetings, keeps important records, and makes sure the company follows legal rules. They act like a bridge between the company's leaders and its shareholders, making sure everything runs smoothly and by the book. Their role is important because it helps the company stay organized and legally compliant.

Emerging growth company regulatory

"Emerging growth company"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Securities Exchange Act of 1934 regulatory

"Pursuant to the requirements of the Securities Exchange Act of 1934"

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Cytek Biosciences disclosed that Valerie Barnett will leave her role as Chief Legal Officer and Corporate Secretary. The company and Ms. Barnett agreed to terminate her position, reflecting a planned transition in the legal and governance leadership team.

Valerie Barnett’s position as Chief Legal Officer and Corporate Secretary will terminate effective June 29, 2026. This provides a short transition window following the June 18, 2026 agreement between her and Cytek Biosciences, Inc.

Valerie Barnett served as Chief Legal Officer and Corporate Secretary at Cytek Biosciences. These roles cover oversight of legal affairs and corporate governance, including board processes and compliance with securities and corporate regulations.

President and Chief Executive Officer Wenbin Jiang, Ph.D., signed the June 2026 report on behalf of Cytek Biosciences. His signature reflects formal company authorization of the disclosed executive change and related regulatory disclosure.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

June 18, 2026

Cytek Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40632

47-2547526

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)


47215 Lakeview Boulevard
Fremont, California		94538
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 922-9835

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.001 per share

CTKB

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b)

On June 18, 2026, Valerie Barnett and Cytek Biosciences, Inc. (the “Company”) agreed that Ms. Barnett’s position as Chief Legal Officer and Corporate Secretary of the Company would terminate effective as of June 29, 2026. Ms. Barnett’s separation is not due to any disagreement with the Company’s operations, policies or practices.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Source: View Original Filing on SEC EDGAR

Cytek Biosciences, Inc.

Date: June 25, 2026

/s/ Wenbin Jiang

Wenbin Jiang, Ph.D.

President and Chief Executive Officer

3 documents